ARQIS accompanies EvlaBio in a € 21 million seed round

Munich — The biotech­no­logy start-up Evla­Bio GmbH, which deve­lops inno­va­tive thera­pies for the treat­ment of left ventri­cu­lar hyper­tro­phy in chro­nic kidney dise­ase, has raised € 21 million in its seed finan­cing round. The finan­cing round was led by the French VC firm Kurma Part­ners, with AdBio Part­ners (Paris, Barce­lona), Boeh­rin­ger Ingel­heim Venture Fund, NRW.Venture (NRW Bank) and High-Tech Grün­der­fonds as co-inves­­tors. The finan­cing round is one of the largest of its kind in the DACH region in recent years. 

Evla­Bio aims to acce­le­rate the comple­tion of precli­ni­cal deve­lo­p­ment and the tran­si­tion to IND-enab­­ling studies. — The start-up’s treat­ment approach origi­nally comes from Lead Disco­very Center GmbH (LDC), a company foun­ded in 2008 by the tech­no­logy trans­fer orga­niza­tion Max Planck Inno­va­tion, and was deve­lo­ped in colla­bo­ra­tion with KHAN Tech­no­logy Trans­fer Fund I GmbH & Co. KG (KHAN‑I).

Evla­Bio, with offices in Düssel­dorf and Zurich, is a life science start-up specia­li­zing in the deve­lo­p­ment of a first-in-class thera­peu­tic for the treat­ment of left ventri­cu­lar hyper­tro­phy in pati­ents with chro­nic kidney disease.

An ARQIS team led by part­ner Dr. Mauritz von Einem, who regu­larly advi­ses start-ups, provi­ded Evla­Bio AG with compre­hen­sive legal support during this finan­cing round. The mandate came about through a perso­nal cont­act with the foun­der of Evla­Bio. Adves­tra advi­sed on Swiss law with a team led by Dr. Alex­an­der von Jeinsen. 

Advi­sor Evla­Bio GmbH: ARQIS (Munich)

Dr. Mauritz von Einem (Part­ner, Tran­sac­tions, Venture Capi­tal, Lead), Johan­nes Landry (Tran­sac­tions, Düssel­dorf), Lisa-Marie Niklas (HR Law, Düssel­dorf), Marcus Noth­hel­fer (IP), of Coun­sel: Prof. Dr. Chris­toph von Einem (Tran­sac­tions, Venture Capi­tal), Coun­sel: Jens Knip­ping (Düssel­dorf), Dennis Reisich (both Tax), Dr. Roua Schmitz (HR Law, Venture Capi­tal), Nora Strat­mann (Commer­cial), Mana­ging Asso­cia­tes: Dr. Hanna Caesar (HR Law, Düssel­dorf), Anselm Graf (Tran­sac­tions, Venture Capi­tal, Rolf. Roua Schmitz (HR Law), Nora Strat­mann (Commer­cial), Mana­ging Asso­cia­tes: Dr. Hanna Caesar (HR Law, Düssel­dorf), Anselm Graf (Tran­sac­tions, Venture Capi­tal), Rolf Tichy (IP), Asso­ciate: Giulia Kögel (Tran­sac­tions, Venture Capital).

About ARQIS

ARQIS is an inde­pen­dent commer­cial law firm that opera­tes inter­na­tio­nally. Around 80 lawy­ers and legal specia­lists advise dome­stic and foreign compa­nies at the highest level on German, Euro­pean and Japa­nese commer­cial law. With its focus groups Tran­sac­tions, HR Law, Japan, Data Law, Risk and Regu­la­tory, the firm is geared towards provi­ding its clients with compre­hen­sive advice. The law firm was foun­ded in 2006 and has offices in Düssel­dorf, Munich and Tokyo as well as a talent hub in Berlin. www.arqis.com.